In 2020, there were more than 1,350 medical conferences in the United States alone, and 447 of them focused on oncology.
With more events popping up in every corner of the world, and the option to attend virtually for many, how can you develop the best conference calendar for what remains of 2021?
Our team of experts put together a list of the top 100 oncology conferences happening in 2021, organized in an easy-to-reference calendar view.
We’ve done even more analysis to identify the top 5 events. Our ranking criteria considered the focus of the conference, the number of abstracts expected, and the attendance of past meetings.
Once you’ve identified your own Top 10, LARVOL can help you maximize your attendance.
LARVOL CONF planners will bring you the information you need when you need it! Our analysts review and manually curate each conference’s abstracts and titles as soon as they’re released and deliver a straightforward spreadsheet tool outlining all sessions, abstracts, identified diseases, products, and mechanisms of action (MOAs).
With the CONF planner, you’ll get the latest facts at each stage of the conference:
In addition to planning ahead for upcoming conferences, it's also important to reflect on the data presented and it's impact on the standard-of-care. LARVOL hosts live, 30-minute panel interviews immediately following major oncology conferences. These panels consist of key opinion leaders (KOLs) and experts in the cancer type at hand discussing 2-3 abstracts, moderated by a LARVOL expert in cancer research.
These conversations present a unique opportunity to further the scientific discussion around new scientific data and are a valuable source of insight into the opinions of experts on the treatments covered in the abstracts.
LARVOL Panel Series are planned for the following oncology conferences in 2021:
To request a demo of VIEW visit here.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.